BOSTON, Oct. 7, 2025 /PRNewswire/ -- Life Molecular Imaging (LMI), a Lantheus company, and SOFIE Biosciences (SOFIE), a national US manufacturer and developer of PET radiopharmaceuticals, announce ...
Expanded clinical indication to include use in both diagnostic assessment and identification of appropriate candidates for FDA-approved amyloid-targeting therapies. Utilization of quantitative amyloid ...
BOSTON, April 24, 2025 /PRNewswire/ -- Life Molecular Imaging (LMI) and PharmaLogic Holdings Corp. (PharmaLogic), a world-class contract development and manufacturing organization (CDMO) and ...
Brain imaging with FDG, NeuraCeq™ and PI-2620 is conducted at the National Cyclotron and PET Centre, Chulabhorn Hospital of the Chulabhorn Royal Academy in Bangkok, where the PET tracers are ...
TOKYO and BERLIN, Nov. 22, 2023 /PRNewswire/ -- CMI Inc. and Life Molecular Imaging (LMI) are pleased to announce that the amyloid-PET diagnostic Neuraceq ® (florbetaben 18 F injection) has been ...
BOSTON, Aug. 20, 2025 /PRNewswire/ -- Life Molecular Imaging (LMI), a Lantheus company, dedicated to developing and offering novel PET radiopharmaceuticals, has expanded its manufacturing and ...
BOSTON, April 24, 2025 /PRNewswire/ -- Life Molecular Imaging (LMI) and PharmaLogic Holdings Corp. (PharmaLogic), a world-class contract development and manufacturing organization (CDMO) and ...
Enhanced the supply capabilities of Neuraceq(R) to increase patient access to beta-amyloid PET imaging BOSTON, April 24, 2025 /PRNewswire/ -- Life Molecular Imaging (LMI) and PharmaLogic Holdings Corp ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback